Arkolith/Insider Trading/KROS/Form 4

Gordon Carl L

DirectorKeros Therapeutics, Inc. (KROS) · full profile →Form 4 · filed Dec 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 21, 2025Disposed to issuer(D)74K$17.75$1.3M45K
Nov 21, 2025Disposed to issuer(D)140K$17.75$2.5M759K

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000947871-25-001084) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML